Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hell J Nucl Med ; 26(2): 140-144, 2023.
Article in English | MEDLINE | ID: mdl-37527050

ABSTRACT

Technetium-99m- diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) is currently used in Europe for the diagnosis of cardiac amyloidosis, being able to distinguish light chain (AL) from transthyretin (TTR) type. We are reporting obvious spleen visualization in two patients suffering the first from proven TTR and the second from AL type of cardiac amyloidosis, with myocardial uptake-as anticipated-only in the first one. We raise the hypothesis that a common uptake mechanism exists for the spleen amyloid regardless of the type of the disease (AL or TTR), and is possibly different than the cardiac uptake mechanism.


Subject(s)
Amyloidosis , Immunoglobulin Light-chain Amyloidosis , Humans , Spleen , Prealbumin , Radiopharmaceuticals , Organotechnetium Compounds , Diphosphonates , Amyloidosis/diagnostic imaging , Radionuclide Imaging
2.
Hell J Nucl Med ; 25(3): 323-325, 2022.
Article in English | MEDLINE | ID: mdl-36576729

ABSTRACT

Technetium-99m (99mTc)-labeled pyrophosphate (PYP) and 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) are currently the most established imaging agents for the diagnosis of cardiac amyloidosis, being able to distinguish light chain (AL) from transthyretin (TTR) type of the disease. We present a pattern of increased uptake in all soft tissues, sparing the organs that are usually most affected.


Subject(s)
Amyloidosis , Immunoglobulin Light-chain Amyloidosis , Humans , Amyloidosis/complications , Amyloidosis/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...